Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "En Vivo EVP6124 Alzheimer"

08:44 EDT 17th April 2014 | BioPortfolio

Matching Channels

Cytoplasmic Protein Tau

One of the main pillars of current drug discovery and development activities in the pharmaceutical industry for Alzheimer's disease is prevention of the accumulation of misfolded proteins, i.e....

Histone Deacetylase HDAC Inhibitors

Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition causes acetylated nuclear...

Nerve growth factor NGF

Nerve growth factor (NGF) is the prototypical member of the family of neurotrophin growth factors that are involved in the growth and survival of nervous tissue. NGF and its receptors, the tyrosine-...

Interleukin 1 IL 1 Receptor IL 1R

Interleukin-1 (IL-1) beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. Current therapy targetin...

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo

Memory Care Living Announces “Light up the Night for Alzheimer’s” in Recongition of Alzheimer’s Disease Awareness Month

Hillsdale, NJ (PRWEB) November 18, 2013 WHO: Memory Care Living, a provider of specialized housing and care for older adults with Alzheimer’s or dementia, and Mayor Max Arnowitz of Hillsdale,...

Eye Test Identifies Alzheimer’s

(BUSINESS WIRE)--Nov 15, 2013--Cognoptix disclosed today at the ‘Clinical Trials on Alzheimer’s Disease’ (CTAD) scientific meeting the strong results of a multi-site clinical trial of its SAPPHI...

Emory University licenses MCI/Alzheimer’s biomarkers to Genomind

Genomind LLC (personalized neuropsychiatric medicine) received an exclusive license to a group of Emory University’s protein markers, which could indicate risk for developing mild cognitive impairme...

Alzheimer’s: Diabetes of the Brain

Alvaro Arjona writes for Life Science Leader on the link between diabetes and Alzheimer’s Disease. The underlying relationship between insulin resistance and dementia has compelled some researchers...

ADDF, Alzheimer’s Society partner on $3M initiative

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Alzheimer’s Society (U.K.) have partnered to provide funding for research in Alzheimer’s disease and related dementias, with the goal of...

Vitamin E for Alzheimer’s

Recently you may have seen headlines like “Vitamin E slows decline in patients with mild Alzheimer’s” or “There’s still no cure for Alzheimer’s disease, but the latest hope for slo...

A Manhattan Project for Alzheimer’s Disease

Earlier this month, at the Alzheimer’s Disease Summit in New York City, BIO‘s President & CEO Jim Greenwood highlighted the need for our nation to think bigger about how we approach Alzhei...

Matching PubMed Articles

Reelin Signaling Pathway Genotypes and Alzheimer Disease in a Spanish Population.

Several reports suggest that the reelin protein could play a role in Alzheimer pathophysiology. This led us to ask whether genetic variability in the reelin pathway may increase the risk of developing...

Rretraction notice to ‘‘1h-MRS can monitor metabolites changes of lateral intraventricular BDNF infusion into a mouse model of Alzheimer’s disease in vivo’’ Neuroscience 245 (2013) 40–49.

Simple method for evaluation of planum temporale pyramidal neurons shrinkage in postmortem tissue of Alzheimer disease patients.

We measured the length of the pyramidal neurons in the cortical layer III in four subregions of the planum temporale (transitions into superior temporal gyrus, Heschl's gyrus, insular cortex, and Sylv...

Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease.

To examine safety, tolerability, and efficacy of PF-04494700, an inhibitor of the receptor for advanced glycation end products (RAGE), in mild to moderate Alzheimer disease (AD).

Don't forget non-Alzheimer dementias.

Dementia is commonly encountered in the elderly, with prevalence increasing with age. Although Alzheimer disease is the most recognized form of dementia, other types have distinct clinical features an...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement